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VACCINE EFFICACY IN SWINE CHALLENGED WITH A
HIGHLY VIRULENT S. TYPHIMURIUM
Axel Neubauer*, Michael B. Roof, John Kolb
Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA
Abstract Vaccination is one of several options to reduce the impact of Salmonella infections in
pork. To demonstrate cross protection against infection with S. Typhimurium, pigs were vaccinat-
ed with a live vaccine (Enterisol® SC-54, Boehringer Ingelheim Vetmedica, Inc.), left as positive
challenge controls or negative, non challenged controls. Vaccination demonstrated significant clini-
cal protection and reduction of lymph node colonization. In addition, nominal improvement in
weight gain was also detected.
Introduction According to a Center of Disease Control and Prevention estimate, 1.4 million indi-
viduals in the US suffer from Salmonella-associated disease every year (Mead et al, 1999). The
most important serovar in this context is S. Typhimurium, which accounts for 21.9% of all
Salmonella isolates. S. Typhimurium is also the most frequently isolated serovar from clinical pig
samples (CDC, 2002). As pork products are frequently associated with clinical Salmonellosis in
humans (Steinback, et al, 1999), S. Typhimurium control in pigs is an important food safety issue.
Whereas S. Typhimurium can cause enterocolitis in pigs, the majority of infections prevail subclini-
cally resulting in substantial economic losses due to a reduction in daily weight gain (Nielsen JN
et al. 1997). The purpose of this study was to determine if Enterisol SC-54, which is based on an
attenuated S. cholerasuis strain, can be used to control S. Typhimurium in pigs.
Materials and Methods The study consisted of 3 groups.  Group 1 (21 animals) was vaccinated
at day 0 with 2 mL Enterisol SC-54. At day 28, group 1 and group 2 (21 animals; challenge con-
trol) were challenged with 2 mL virulent S. Typhimurium (BIVI 02-04) culture. Group 3 (20 animals)
served as strict control. Criteria to determine protection included display of clinical symptoms,
weight gain, fecal shedding of Salmonella, and the results of the pathological examination (pres-
ence of gross-lesions, colonization of inner organs by Salmonella), which was conducted two
weeks after challenge. Shedding of the vaccine strain and seroconversion (IDEXX Salmonella Herd
CheckTM) were monitored. The data was analyzed using a SAS environment.  Applied tests
included ANOVA and Chi-Square/Fisher's Exact analysis. 
Results Compared to the non-vaccinated challenge control group, the Enterisol SC-54 group
showed significantly (p#0.05) fewer clinical symptoms relevant to their general well-being. There
was also a significant (p#0.05) reduction in the prevalence of respiratory symptoms, loose
feces/diarrhea, and decreased hydration. A significant (p#0.05) reduction in the prevalence of
enteropathy/enteritis affecting the small intestine, as well as a significant (P#0.05) reduction of
the Salmonella recovery rate from the mesenteric lymph node compared to non-vaccinated pigs
was also observed in the Enterisol SC-54 vaccinated animals (Table 1).
In addition, the vaccinated animals showed a nominal increase in average daily weight gain
post-challenge (days 27-42; 486 vs. 386 gm/day) and weight at the end of the trial (day 42; 28.2
vs. 26.2 kg) compared to the challenge control group.  Fecal shedding post-challenge was not
completely prevented by vaccination.  
Discussion One of the vaccinated animals died of Salmonellosis after challenge, compared to
four animals in the challenge control group.  The animals did not sero-convert following immuniza-
tion. Statistical significant shedding of the vaccine strain was not observed in the Enterisol SC-54
animals compared to the non-vaccinated controls. The results of this study demonstrated that vac-
cination with Enterisol SC-54 resulted in significant levels of protection following challenge with a
virulent S. Typhimurium strain. 
Conclusions This indicates that Enterisol SC-54 can be a valuable asset in the control of S.
Typhimurium due to the reduction of economic losses from S. Typhimurium-associated clinical
and subclinical symptoms, as demonstrated in prior studies. Vaccination with Enterisol SC-54
does at the same time not impair serological evaluation of individual animals or whole herds due
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Table indicates positive findings in %
Enterisol®
SC-54
Challenge
Control
Strict Control
Impaired General Well Being 2.25* 7.64 0 .00
Respiratory symptoms 0.00* 5.05 0.00
Decreased hydration 0.78* 4.80 0.00
Loose feces/diarrhea 9.71* 19.43 0.00
Enteropathy/enteritis (small intestine) 10.00* 73.33 35.29
Salmonella recovery MLN 36.84* 73.33 0.00
to the lack of detectable seroconversion following immunization and reduces mesenteric lymph
node colonization.
References
CDC. Salmonella Surveillance Summary, 2002. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2003.
Mead PS et al. Food related Illness and death in the United States. Emerg Infect Dis. 1999:607-625.
Nielsen JN et al. Productivity and Salmonella incidence of swine reared in differing management systems. Purdue University
1997 Swine Day Report.
Steinbach G, Hartung M. [Attempt to estimate the share of human Salmonella infections, which are attributable to Salmonella
originating from swine] Berl Munch Tierarztl Wochenschr. 1999:296-300.
Table 1: Statistical significant differences between groups regarding clinical, pathological,
and bacteriological findings. *Differences between Enterisol SC-54 and Challenge
Control groups are statistical significant (p<0.05; Chi-Square/Fischer's Exact analysis). 
